Advertisement
Screener

GALECTIN THERAPEUTICS INC. (GALT) Investing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

GALECTIN THERAPEUTICS INC. Investing Cash Flow

GALECTIN THERAPEUTICS INC. (GALT) reported Investing Cash Flow of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.

Financial Statements › Cash Flow

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-03-31

  • GALECTIN THERAPEUTICS INC. net cash provided by (used in) investing activities for the quarter ending 2014-03-31 was -$400.00K.
  • GALECTIN THERAPEUTICS INC. net cash provided by (used in) investing activities for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
  • GALECTIN THERAPEUTICS INC. net cash provided by (used in) investing activities for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
  • GALECTIN THERAPEUTICS INC. net cash provided by (used in) investing activities for the quarter ending 2013-06-30 was $0.00.
  • GALECTIN THERAPEUTICS INC. net cash provided by (used in) investing activities for fiscal 2025 was $0.00.
  • GALECTIN THERAPEUTICS INC. net cash provided by (used in) investing activities for fiscal 2024 was $0.00.
  • GALECTIN THERAPEUTICS INC. net cash provided by (used in) investing activities for fiscal 2023 was $0.00.
  • GALECTIN THERAPEUTICS INC. net cash provided by (used in) investing activities for fiscal 2022 was $0.00.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 12 monthNet Cash Provided by (Used in) Investing Activities 132 monthNet Cash Provided by (Used in) Investing Activities 135 monthNet Cash Provided by (Used in) Investing Activities 138 monthNet Cash Provided by (Used in) Investing Activities 141 monthNet Cash Provided by (Used in) Investing Activities 144 monthNet Cash Provided by (Used in) Investing Activities 147 monthNet Cash Provided by (Used in) Investing Activities 150 monthNet Cash Provided by (Used in) Investing Activities 153 monthNet Cash Provided by (Used in) Investing Activities 156 monthNet Cash Provided by (Used in) Investing Activities 159 monthNet Cash Provided by (Used in) Investing Activities 162 monthNet Cash Provided by (Used in) Investing Activities 165 month
2025-12-31$0.00
10-K · filed 2026-03-31
2024-12-31$0.00
10-K · filed 2026-03-31
2023-12-31$0.00
10-K · filed 2025-03-31
2022-12-31$0.00
10-K · filed 2024-03-29
2021-12-31$0.00
10-K · filed 2023-03-30
2020-12-31$0.00
10-K · filed 2022-03-31
2018-12-31$0.00
10-K · filed 2019-03-06
2017-12-31$0.00
10-K · filed 2019-03-06
2014-03-31-$400.00K
10-Q · filed 2014-05-13
-$400.00K
derived: sum of 2 quarters · filed 2014-05-13
-$400.00K
derived: sum of 3 quarters · filed 2014-05-13
-$400.00K
derived: sum of 4 quarters · filed 2014-05-13
-$1.24M
10-Q · filed 2014-05-13
2013-12-31$0.00
derived: 10-K 162 month − 10-Q 159 month · filed 2014-03-21
$0.00
derived: sum of 2 quarters · filed 2014-03-21
$0.00
derived: sum of 3 quarters · filed 2014-03-21
$0.00
derived: sum of 4 quarters · filed 2014-03-21
-$835.00K
10-K · filed 2014-03-21
2013-09-30$0.00
derived: 10-Q 159 month − 10-Q 156 month · filed 2013-11-12
$0.00
derived: sum of 2 quarters · filed 2013-11-12
$0.00
derived: sum of 3 quarters · filed 2013-11-12
$56.00K
derived: sum of 4 quarters · filed 2014-03-21
-$835.00K
10-Q · filed 2013-11-12
2013-06-30$0.00
derived: 10-Q 156 month − 10-Q 153 month · filed 2013-08-14
$0.00
derived: sum of 2 quarters · filed 2013-08-14
$56.00K
derived: sum of 3 quarters · filed 2014-03-21
$64.00K
derived: sum of 4 quarters · filed 2014-03-21
-$835.00K
10-Q · filed 2013-08-14
2013-03-31$0.00
derived: 10-Q 153 month − 10-K 150 month · filed 2013-05-10
$56.00K
derived: sum of 2 quarters · filed 2014-03-21
$64.00K
derived: sum of 3 quarters · filed 2014-03-21
$64.00K
derived: sum of 4 quarters · filed 2014-03-21
-$835.00K
10-Q · filed 2013-05-10
2012-12-31$56.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21
$64.00K
derived: sum of 2 quarters · filed 2014-03-21
$64.00K
derived: sum of 3 quarters · filed 2014-03-21
$64.00K
10-K · filed 2014-03-21
-$835.00K
10-K · filed 2013-03-29
2012-09-30$8.00K
derived: 10-Q 147 month − 10-Q 144 month · filed 2012-11-09
$8.00K
derived: sum of 2 quarters · filed 2012-11-09
$8.00K
10-Q · filed 2013-11-12
$3.00K
derived: sum of 4 quarters · filed 2013-03-29
-$891.00K
10-Q · filed 2012-11-09
2012-06-30$0.00
derived: 10-Q 144 month − 10-Q 141 month · filed 2012-08-10
$0.00
derived: sum of 2 quarters · filed 2012-08-10
-$5.00K
derived: sum of 3 quarters · filed 2013-03-29
-$10.00K
derived: sum of 4 quarters · filed 2013-03-29
-$899.00K
10-Q · filed 2012-08-10
2012-03-31$0.00
derived: 10-Q 141 month − 10-K 138 month · filed 2012-05-11
-$5.00K
derived: sum of 2 quarters · filed 2013-03-29
-$10.00K
derived: sum of 3 quarters · filed 2013-03-29
-$899.00K
10-Q · filed 2012-05-11
2011-12-31-$5.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29
-$10.00K
derived: sum of 2 quarters · filed 2013-03-29
-$15.00K
10-K · filed 2013-03-29
-$899.00K
10-K · filed 2012-03-30
2011-09-30-$5.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
-$10.00K
10-Q · filed 2012-11-09
-$894.00K
10-Q · filed 2011-11-10
2011-06-30-$5.00K
10-Q · filed 2012-08-10
-$889.00K
10-Q · filed 2011-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Rezolute, Inc. (RZLT)United States$0.382B-6.45
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63